首页 > 最新文献

Blood Research最新文献

英文 中文
A case report of thrombotic thrombocytopenic purpura-like syndrome after Coronavirus disease 2019 vaccination. 2019冠状病毒病疫苗接种后发生血栓性血小板减少性紫癜样综合征1例报告。
IF 2.2 Q3 Medicine Pub Date : 2023-06-30 DOI: 10.5045/br.2023.2023036
Sua Noh, Sang A Kim, Ji Yun Lee, Jeong Ok Lee, Soo Mee Bang
Fig. 1. Clinical course and changes in laboratory findings. With steroid treatment plus plasmapheresis, the patient’s hemoglobin levels and platelet counts recovered rapidly. Renal biopsy was performed during the administration of high-dose steroids. Fig. 2. Light microscopy of the kidney biopsy. (A) Endothelial swelling and some intraglomerular thrombi were observed on H&E-stained specimens (×500). (B) Segmental occlusion of the glomerular capillary lumen and thickening of the shrunken capillary wall with double contours were observed using PAS staining (×400). A case report of thrombotic thrombocytopenic purpura-like syndrome after Coronavirus disease 2019 vaccination
{"title":"A case report of thrombotic thrombocytopenic purpura-like syndrome after Coronavirus disease 2019 vaccination.","authors":"Sua Noh, Sang A Kim, Ji Yun Lee, Jeong Ok Lee, Soo Mee Bang","doi":"10.5045/br.2023.2023036","DOIUrl":"https://doi.org/10.5045/br.2023.2023036","url":null,"abstract":"Fig. 1. Clinical course and changes in laboratory findings. With steroid treatment plus plasmapheresis, the patient’s hemoglobin levels and platelet counts recovered rapidly. Renal biopsy was performed during the administration of high-dose steroids. Fig. 2. Light microscopy of the kidney biopsy. (A) Endothelial swelling and some intraglomerular thrombi were observed on H&E-stained specimens (×500). (B) Segmental occlusion of the glomerular capillary lumen and thickening of the shrunken capillary wall with double contours were observed using PAS staining (×400). A case report of thrombotic thrombocytopenic purpura-like syndrome after Coronavirus disease 2019 vaccination","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/39/br-58-2-116.PMC10310487.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10111926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum. 勘误表。
IF 2.2 Q3 Medicine Pub Date : 2023-06-30 DOI: 10.5045/br.2023.2022218e1
{"title":"Erratum.","authors":"","doi":"10.5045/br.2023.2022218e1","DOIUrl":"https://doi.org/10.5045/br.2023.2022218e1","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/f3/br-58-2-124.PMC10310493.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward. 基于诱导结束MRD评估的早期治疗强化使用新型药物治疗ETP-ALL-可能是前进的方向。
IF 2.2 Q3 Medicine Pub Date : 2023-06-30 DOI: 10.5045/br.2023.2022241
Pritish Chandra Patra, Sujay Rainchwar, Reema Singh, Rohan Halder, Pallavi Mehta, Megha Verma, Rayaz Ahmed, Jyoti Shankar Raichaudhuri, Dinesh Bhurani, Narendra Agrawal, Suman Pramanik
TO THE EDITOR: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) arises from early thymic progenitor cells that migrate from the bone marrow to the thymus and have the potential to differentiate into myeloid/dendritic or T cells. Gene expression profiling has revealed that ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells. ETP leukemic cells do not express CD1a, CD8, and CD5 (negative to dim). Instead, these cells express ≥1 stem cell/myeloid markers. However, in addition to other ETP-ALL diagnostic criteria, near-ETP-ALL usually shows brighter CD5 [1]. In the literature, the data on ETP-ALL varies markedly, ranging from outcomes poorer than those of other T-ALL to comparable outcomes, with complete remission (CR) rates ranging from 70% to more than 90% [2-5]. Combination chemotherapy is the mainstay treatment. ETP-ALL represents a high-risk subtype of ALL. These outcomes highlight the need for alternative therapeutic approaches that are prognosis-based, and ideally, aiming for minimal residual disease (MRD)negative remission, which may help in preventing relapse. Here, we present the results of a retrospective study on ETP/near-ETP-ALL in the Department of Hemato-Oncology of a dedicated cancer hospital in North India.
{"title":"End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.","authors":"Pritish Chandra Patra, Sujay Rainchwar, Reema Singh, Rohan Halder, Pallavi Mehta, Megha Verma, Rayaz Ahmed, Jyoti Shankar Raichaudhuri, Dinesh Bhurani, Narendra Agrawal, Suman Pramanik","doi":"10.5045/br.2023.2022241","DOIUrl":"https://doi.org/10.5045/br.2023.2022241","url":null,"abstract":"TO THE EDITOR: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) arises from early thymic progenitor cells that migrate from the bone marrow to the thymus and have the potential to differentiate into myeloid/dendritic or T cells. Gene expression profiling has revealed that ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells. ETP leukemic cells do not express CD1a, CD8, and CD5 (negative to dim). Instead, these cells express ≥1 stem cell/myeloid markers. However, in addition to other ETP-ALL diagnostic criteria, near-ETP-ALL usually shows brighter CD5 [1]. In the literature, the data on ETP-ALL varies markedly, ranging from outcomes poorer than those of other T-ALL to comparable outcomes, with complete remission (CR) rates ranging from 70% to more than 90% [2-5]. Combination chemotherapy is the mainstay treatment. ETP-ALL represents a high-risk subtype of ALL. These outcomes highlight the need for alternative therapeutic approaches that are prognosis-based, and ideally, aiming for minimal residual disease (MRD)negative remission, which may help in preventing relapse. Here, we present the results of a retrospective study on ETP/near-ETP-ALL in the Department of Hemato-Oncology of a dedicated cancer hospital in North India.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/7a/br-58-2-112.PMC10310492.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10110838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An alternative approach to confirm mixed lineage involvement in acute leukemia with KMT2A rearrangement-an illustrative report. 另一种方法,以确认混合谱系参与急性白血病与KMT2A重排-说明性报告。
IF 2.2 Q3 Medicine Pub Date : 2023-06-30 DOI: 10.5045/br.2023.2023084
Debadrita Ray, Sreejesh Sreedharanunni, Anand Balakrishnan, Praveen Sharma, Nabhajit Mallik, Srinivasan Peyam, Man Updesh Singh Sachdeva
REFERENCES 1. Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica 2017; 102:2134-40. 2. Shimoni A. Relapse of acute leukemia after a second allogeneic stemcell transplantation; is there any hope for cure? Bone Marrow Transplant 2022;57:336-7. 3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617‐29. 4. Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 2021;100:959‐68. 5. Qasrawi A, Gomes V, Chacko CA, et al. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leuk Res 2020;89:106301. 6. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362‐75. 7. Fleischmann M, Scholl S, Frietsch JJ, et al. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2022;148:3191‐202. 8. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022; 40:855‐65. 9. Wang N, He J, Liu F. Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases. Chemotherapy 2022;67:178-82. 10. Klocke H, Dong ZM, O'Brien C, et al. Venetoclax and decitabine for T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS). Case Rep Hematol 2020;2020:8811673. 11. Zhao P, Ni M, Ma D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2022;101:119‐30. 12. Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 2021;11:463. 13. Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol 2019;94:358-62. 14. Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2019;134(Suppl 1):2640.
{"title":"An alternative approach to confirm mixed lineage involvement in acute leukemia with <i>KMT2A</i> rearrangement-an illustrative report.","authors":"Debadrita Ray,&nbsp;Sreejesh Sreedharanunni,&nbsp;Anand Balakrishnan,&nbsp;Praveen Sharma,&nbsp;Nabhajit Mallik,&nbsp;Srinivasan Peyam,&nbsp;Man Updesh Singh Sachdeva","doi":"10.5045/br.2023.2023084","DOIUrl":"https://doi.org/10.5045/br.2023.2023084","url":null,"abstract":"REFERENCES 1. Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica 2017; 102:2134-40. 2. Shimoni A. Relapse of acute leukemia after a second allogeneic stemcell transplantation; is there any hope for cure? Bone Marrow Transplant 2022;57:336-7. 3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617‐29. 4. Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 2021;100:959‐68. 5. Qasrawi A, Gomes V, Chacko CA, et al. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leuk Res 2020;89:106301. 6. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362‐75. 7. Fleischmann M, Scholl S, Frietsch JJ, et al. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2022;148:3191‐202. 8. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022; 40:855‐65. 9. Wang N, He J, Liu F. Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases. Chemotherapy 2022;67:178-82. 10. Klocke H, Dong ZM, O'Brien C, et al. Venetoclax and decitabine for T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS). Case Rep Hematol 2020;2020:8811673. 11. Zhao P, Ni M, Ma D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2022;101:119‐30. 12. Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 2021;11:463. 13. Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol 2019;94:358-62. 14. Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2019;134(Suppl 1):2640.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/e0/br-58-2-120.PMC10310490.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9791403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overexpression of S100A9 in donor T cells is associated with reconstitution of gut microbiota and outcome of allogeneic hematopoietic stem cell transplantation. 供体T细胞中S100A9的过度表达与肠道微生物群的重建和异基因造血干细胞移植的结果有关。
IF 2.3 Q2 HEMATOLOGY Pub Date : 2023-06-30 Epub Date: 2023-04-07 DOI: 10.5045/br.2023.2022238
Sena Kim, Sora Lim, Farnaz Razmkhah, Jaebok Choi
{"title":"Overexpression of S100A9 in donor T cells is associated with reconstitution of gut microbiota and outcome of allogeneic hematopoietic stem cell transplantation.","authors":"Sena Kim, Sora Lim, Farnaz Razmkhah, Jaebok Choi","doi":"10.5045/br.2023.2022238","DOIUrl":"10.5045/br.2023.2022238","url":null,"abstract":"","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/76/68/br-58-2-105.PMC10310486.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10109762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WITHDRAWN: Mutational analysis of the F8 gene and phenotypic characterization of Hemophilia A. 血友病A的F8基因突变分析及表型特征。
IF 2.2 Q3 Medicine Pub Date : 2023-06-08 DOI: 10.5045/br.2023.2022237
Suresh Hanagavadi, Priyanka Indoria, K S Rajashekar, Rajat Hegde, Smita Hegde, Sujayendra Kulkarni, Chanda Varshini Sindhiya, Vardendra Kulkarni, Suyamindra S Kulkarni, Pramod B Gai

This article has been withdrawn as the request of the author(s) and/or Editors. The Publisher apologizes for any inconvenience this may cause.

应作者和/或编辑的要求,本文已被撤回。对于由此造成的任何不便,出版商深表歉意。
{"title":"WITHDRAWN: Mutational analysis of the <i>F8</i> gene and phenotypic characterization of Hemophilia A.","authors":"Suresh Hanagavadi,&nbsp;Priyanka Indoria,&nbsp;K S Rajashekar,&nbsp;Rajat Hegde,&nbsp;Smita Hegde,&nbsp;Sujayendra Kulkarni,&nbsp;Chanda Varshini Sindhiya,&nbsp;Vardendra Kulkarni,&nbsp;Suyamindra S Kulkarni,&nbsp;Pramod B Gai","doi":"10.5045/br.2023.2022237","DOIUrl":"https://doi.org/10.5045/br.2023.2022237","url":null,"abstract":"<p><p>This article has been withdrawn as the request of the author(s) and/or Editors. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9675490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase. 阿西米尼:BCR: ABL1激酶的一流变构抑制剂。
IF 2.2 Q3 Medicine Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023017
Eun-Ji Choi

The prognosis of patients with chronic phase (CP) chronic myeloid leukemia (CML) has significantly improved due to the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, approximately 15‒20% of patients ultimately experience treatment failure due to resistance or intolerance to TKI therapy. As the prognosis of patients in whom multiple TKIs fail remains poor, an optimal therapeutic approach is required to treat the condition. Asciminib, an allosteric inhibitor that targets ABL1 myristoyl pocket, has been approved by the Food and Drug Administration for use in patients with CP-CML resistant or intolerant to ≥2 prior TKIs or those with T315I mutation. In a phase 1 trial, asciminib monotherapy showed a relatively favorable safety profile and potent efficacy in patients with and without the T315I mutation. In a subsequent phase 3 trial, asciminib treatment was associated with a significantly higher major molecular response rate and lower discontinuation rate than bosutinib in patients with CP-CML for whom two previous TKIs failed. Several clinical trials are being performed in various clinical settings to evaluate the role of asciminib as a frontline treatment for newly diagnosed CP-CML, either as a single agent or in combination with other TKIs as a second-line or additive treatment to improve treatment-free or deep remission. This review summarizes the incidence, available therapies, and outcomes of patients with CP-CML who experienced treatment failure, the mechanism of action, preclinical and clinical data, and ongoing trials for asciminib.

由于有效的BCR::ABL1酪氨酸激酶抑制剂(TKIs)的发展,慢性粒细胞白血病(CML)患者的预后显著改善。然而,大约15-20%的患者由于对TKI治疗的耐药或不耐受而最终经历治疗失败。由于多次tki失败的患者预后仍然很差,因此需要一种最佳的治疗方法来治疗这种疾病。阿西米尼(Asciminib)是一种靶向ABL1豆豆酰基口袋的变抗抑制剂,已被美国食品和药物管理局批准用于CP-CML耐药或不耐受≥2个TKIs或T315I突变的患者。在一项1期试验中,阿西米尼单药治疗在T315I突变和非T315I突变患者中显示出相对有利的安全性和有效的疗效。在随后的3期试验中,阿西米尼治疗与波舒替尼相比,在先前两次TKIs失败的CP-CML患者中,主要分子反应率明显更高,停药率更低。一些临床试验正在各种临床环境中进行,以评估阿西米尼作为新诊断的CP-CML的一线治疗的作用,无论是作为单一药物还是与其他TKIs联合作为二线或辅助治疗,以改善无治疗或深度缓解。本文综述了阿西米尼治疗失败的CP-CML患者的发病率、可用治疗方法和结局、作用机制、临床前和临床数据以及正在进行的试验。
{"title":"Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.","authors":"Eun-Ji Choi","doi":"10.5045/br.2023.2023017","DOIUrl":"https://doi.org/10.5045/br.2023.2023017","url":null,"abstract":"<p><p>The prognosis of patients with chronic phase (CP) chronic myeloid leukemia (CML) has significantly improved due to the development of potent BCR::ABL1 tyrosine kinase inhibitors (TKIs). However, approximately 15‒20% of patients ultimately experience treatment failure due to resistance or intolerance to TKI therapy. As the prognosis of patients in whom multiple TKIs fail remains poor, an optimal therapeutic approach is required to treat the condition. Asciminib, an allosteric inhibitor that targets ABL1 myristoyl pocket, has been approved by the Food and Drug Administration for use in patients with CP-CML resistant or intolerant to ≥2 prior TKIs or those with T315I mutation. In a phase 1 trial, asciminib monotherapy showed a relatively favorable safety profile and potent efficacy in patients with and without the T315I mutation. In a subsequent phase 3 trial, asciminib treatment was associated with a significantly higher major molecular response rate and lower discontinuation rate than bosutinib in patients with CP-CML for whom two previous TKIs failed. Several clinical trials are being performed in various clinical settings to evaluate the role of asciminib as a frontline treatment for newly diagnosed CP-CML, either as a single agent or in combination with other TKIs as a second-line or additive treatment to improve treatment-free or deep remission. This review summarizes the incidence, available therapies, and outcomes of patients with CP-CML who experienced treatment failure, the mechanism of action, preclinical and clinical data, and ongoing trials for asciminib.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/45/br-58-s1-s29.PMC10133857.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Practical issues in CAR T-cell therapy. CAR - t细胞治疗中的实际问题。
IF 2.2 Q3 Medicine Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023015
Ja Min Byun

Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.

嵌合抗原受体(CAR) t细胞疗法在个性化癌症治疗方面取得了革命性的进展。在生产过程中,患者自身的t细胞通过基因工程来表达一种与肿瘤抗原结合的合成受体。然后将CAR - t细胞扩增用于临床,并注入患者体内以攻击癌细胞。尽管CAR - t细胞疗法被认为是癌症免疫治疗的重大突破,但它并非没有局限性。在这篇综述中,我们讨论了在韩国有效的CAR - t细胞治疗的障碍。
{"title":"Practical issues in CAR T-cell therapy.","authors":"Ja Min Byun","doi":"10.5045/br.2023.2023015","DOIUrl":"https://doi.org/10.5045/br.2023.2023015","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/5f/br-58-s1-s11.PMC10133847.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9826121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
T-large granular lymphocytic leukemia. t大颗粒淋巴细胞白血病。
IF 2.2 Q3 Medicine Pub Date : 2023-04-30 DOI: 10.5045/br.2023.2023037
Sang Hyuk Park, Yoo Jin Lee, Youjin Kim, Hyun-Ki Kim, Ji-Hun Lim, Jae-Cheol Jo

T-cell large granular lymphocyte (T-LGL) leukemia is characterized by clonal expansion of cytotoxic T cells resulting in cytopenia. The proliferation of clonal LGLs is caused by prolonged antigenic stimulation, which leads to apoptotic dysregulation owing mainly to the constitutive activation of survival pathways, notably the JAK/STAT pathway. Understanding how leukemic T-LGL persists can aid in the development of future immunosuppressive therapies. In this review, we summarize the diagnosis and current standard of therapy for T-LGL leukemia, as well as recent advances in clinical trials.

T细胞大颗粒淋巴细胞(T- lgl)白血病的特点是细胞毒性T细胞克隆扩增导致细胞减少。克隆性LGLs的增殖是由长时间的抗原刺激引起的,这主要是由于生存通路的组成性激活,特别是JAK/STAT通路,导致凋亡失调。了解白血病T-LGL如何持续可以帮助开发未来的免疫抑制疗法。本文就T-LGL白血病的诊断、治疗标准以及临床研究的最新进展作一综述。
{"title":"T-large granular lymphocytic leukemia.","authors":"Sang Hyuk Park,&nbsp;Yoo Jin Lee,&nbsp;Youjin Kim,&nbsp;Hyun-Ki Kim,&nbsp;Ji-Hun Lim,&nbsp;Jae-Cheol Jo","doi":"10.5045/br.2023.2023037","DOIUrl":"https://doi.org/10.5045/br.2023.2023037","url":null,"abstract":"<p><p>T-cell large granular lymphocyte (T-LGL) leukemia is characterized by clonal expansion of cytotoxic T cells resulting in cytopenia. The proliferation of clonal LGLs is caused by prolonged antigenic stimulation, which leads to apoptotic dysregulation owing mainly to the constitutive activation of survival pathways, notably the JAK/STAT pathway. Understanding how leukemic T-LGL persists can aid in the development of future immunosuppressive therapies. In this review, we summarize the diagnosis and current standard of therapy for T-LGL leukemia, as well as recent advances in clinical trials.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/2c/br-58-s1-s52.PMC10133854.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9456509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transfusion support in hematopoietic stem cell transplantation. 造血干细胞移植中的输血支持。
IF 2.2 Q3 Medicine Pub Date : 2023-04-30 Epub Date: 2023-02-27 DOI: 10.5045/br.2023.2023004
Dong Wook Jekarl, Jae Kwon Kim, Jay Ho Han, Howon Lee, Jaeeun Yoo, Jihyang Lim, Yonggoo Kim

Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.

造血干细胞移植(HSCT)的输血支持是支持性护理的重要组成部分,应将相容性血液输注到受者体内。由于首先考虑白细胞抗原(HLA)匹配,并且血型不会阻碍HSCT,因此会出现主要、次要、双向和RhD不兼容,这可能会阻碍输血并导致不良事件。血液制品中的白细胞减少是经常使用的,除血浆外,应对血液制品进行照射。为了减轻不相容性和不良事件,应考虑当地输血指南、医院输血委员会和患者管理。
{"title":"Transfusion support in hematopoietic stem cell transplantation.","authors":"Dong Wook Jekarl,&nbsp;Jae Kwon Kim,&nbsp;Jay Ho Han,&nbsp;Howon Lee,&nbsp;Jaeeun Yoo,&nbsp;Jihyang Lim,&nbsp;Yonggoo Kim","doi":"10.5045/br.2023.2023004","DOIUrl":"10.5045/br.2023.2023004","url":null,"abstract":"<p><p>Transfusion support for hematopoietic stem cell transplantation (HSCT) is an essential part of supportive care, and compatible blood should be transfused into recipients. As leukocyte antigen (HLA) matching is considered first and as the blood group does not impede HSCT, major, minor, bidirectional, and RhD incompatibilities occur that might hinder transfusion and cause adverse events. Leukocyte reduction in blood products is frequently used, and irradiation should be performed for blood products, except for plasma. To mitigate incompatibility and adverse events, local transfusion guidelines, hospital transfusion committees, and patient management should be considered.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/be/ad/br-58-s1-s1.PMC10133853.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10294836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Blood Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1